Millions in US use unapproved GLP-1s—and use them in unapproved ways
Cost and access barriers are pushing people to modified use and unapproved versions.
The trend of using unapproved GLP-1s in the US, often in modified ways, highlights a critical issue in the healthcare system - the struggle for accessibility and affordability of essential medications. GLP-1s, or glucagon-like peptide-1 receptor agonists, are typically prescribed for the treatment of type 2 diabetes and have also been approved for weight management. However, their high cost and limited accessibility have led to a black market of unapproved versions and creative, though potentially risky, uses of these drugs.
The fact that millions are resorting to such measures underscores the severity of the cost and access barriers in healthcare. It also points to a significant gap in the system where regulatory oversight and public health policies are failing to meet the needs of the population. For app developers and the tech industry, this situation presents both challenges and opportunities. There's a clear need for digital solutions that can provide education, support, and potentially safer alternatives for those seeking affordable healthcare options.
As this situation evolves, it will be crucial to watch how regulatory bodies and healthcare providers respond to the widespread use of unapproved GLP-1s. Additionally, the role of technology, including apps, in addressing the gap between healthcare needs and accessibility will be significant. Apps could offer platforms for education, community support, and even innovative, approved methods of accessing necessary medications. The intersection of healthcare, technology, and policy will be a key area to monitor for developments that could impact both public health and the app economy.
Originally reported by arstechnica.com. AppNewsletter adds analysis for ai & agent economy readers.